Aims We carried out a screening of survival factors released from cells exposed to simulated ischemia and reperfusion (sI/R) using the embryonic rat heart-derived cell line H9c2 and examined the physiological role of the identified factor.
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Introduction Ischemia-reperfusion of the heart is a major disease status arising from acute myocardial infarction, cardiopulmonary bypass surgery, and heart transplantation. Following the recanalization of an infarct-damaged coronary artery, an expansion of the ischemic region is observed as acute dilation and thinning of the infarcted area, hypertrophy of the remaining myocardium, induction of apoptotic cell death in the surrounding region of ischemia, and an increase in cardiac fibrosis in the infarcted region 1 . These processes are referred to as remodelling, and have been observed not only in cardiomyocytes directly exposed to ischemia-reperfusion, but also in cells surrounding the ischemic region. This suggests that cardiomyocytes exposed to ischemia-reperfusion release a variety of factors that transmit some signal(s) to the surrounding cells.
It is well known that the heart functions as an endocrine tissue by secreting hormonal factors in addition to its role as a pump to propel blood to other tissues of the body 2, 3 .
Molecules released from the heart, such as nitric oxide, prostaglandins, adenosine, and endothelin, are involved in the regulation of the cardiovascular system after myocardial ischemia [4] [5] [6] [7] [8] . In addition to these small molecules, inflammatory cytokines are also released from cardiomyocytes after ischemia and reperfusion 9 . For example, tumor necrosis factor-α is produced in the ischemic heart, and is involved in cardiac contractile depression through the inhibition of the sarcoplasmic ryanodine receptor 10 . The inflammatory cytokines interleukin (IL)-1β and IL-6 are also released from the myocardium following ischemia and reperfusion, and are secreted into the blood. These factors generated in the ischemic heart not only aggravate cardiac contractility, but also lead to dysfunction in intact cardiomyocytes [11] [12] [13] . Growth factors are reported to act as survival factors released during myocardial ischemia 14, 15, 16 , 17, 18 . Most growth factors are involved in angiogenesis to the infarcted area as well as in inhibiting apoptotic cell death, thus leading to the protection of the myocardium from ischemic injury through the activation of signal transduction molecules 19 . However,
these factors have the ability to stimulate the proliferation of various cell types, including fibroblasts, hepatocytes, and lymphocytes, which may be a risk in heart disease 20 . During oxidative stress caused by ischemia and reperfusion, we have demonstrated that the activation of extracellular signal-regulated kinase1/2 (ERK1/2) maintains contractility and survival in rat cardiomyocytes through the up-regulation of glycolytic α-enolase [21] [22] [23] , strongly suggesting that the activation of ERK1/2 might be required to restore heart function following ischemic injury. Although Urocortin as a substance that induces ERK1/2 activation and improves myocardial dysfunction during oxidative stress has been demonstrated, a novel cardioprotective factor would be beneficial for patients with ischemic heart disease 24 .
In the present studies, we identified a novel cardioprotective factor released from a rat heart-derived cell line, H9c2 cells, during simulated ischema (oxygen and glucose deprivation) and simulated reperfusion (oxygen and glucose addition) (sI/R). This factor was purified from polypeptides released from cells as a p36 protein with survival activity and identified as the lactate dehydrogenase muscle subunit (M-LDH ] i ) overload.
M-LDH was found to activate ERK1/2 and suppress the reduction of cardiac output by ischemia/reperfusion in isolated mouse heart. These findings suggest that M-LDH is released from cardiomyocytes during ischemia-reperfusion and plays a cardioprotective role against myocardial injury arising from oxidative stress in the ischemic heart.
DMEM without 10 % FBS, and each of the eluate fractions was added to a well. The plates were then incubated for 24 hr in a CO 2 incubator. Cell number was determined by a modified MTT assay as described previously (Dojindo Chemicals, Kumamoto, Japan) 27 .
Purification of survival factors
Twenty liters of the supernatant of H9c2 cells (approximately 2X10 10 cells) exposed to simulated ischemia for 2 hr and simulated reperfusion for 24 hr was used for the purification of survival factors. Ammonium sulfate was added to the supernatant to a final concentration of 80 %, and the mixture was stirred for 24 hr at 4 °C. The sample was centrifuged for 30 min at 4 °C (x18000 g), the supernatant was removed, and the pellet was stored at -80 °C for purification of survival factors. The pellet was dissolved, and dialyzed against 10 mM
Tris-HCl (pH 7.0) for 24 hr at 4 °C. The sample was loaded onto a column of HiTrap heparin-Sepharose (5 ml) (GE Healthcare UK Ltd., Buckinghamshire, UK) equilibrated with the same buffer. Bound proteins were eluted with a linear NaCl gradient from 0 mM to 1000 mM in 30 min at 1 ml/min. A part of the pooled fractions was applied to gel filtration on Micro Bio-Spin 6 (Bio-Rad, Richmond, CA) to determine survival activity and to detect proteins by SDS-PAGE and silver staining. After the active fractions were pooled and the salt was removed by gel filtration, the sample was applied to a Resourse Q column (GE Healthcare, Milwaukee, WI) equilibrated with 10 mM Tris-HCl, pH 8.0. The column was eluted with a stepwise NaCl gradient as shown in Fig. 1B over 30 min at 1 ml/min, and 1 ml fractions were collected. The active fractions were desalted and concentrated to 0.05 ml by passage through a centrifugal filter device (Millipore, Bedford, MA).
Identification of survival factors by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS)
The sample was subjected to SDS-PAGE, and stained with a mass spectrometry-compatible
Accepted Manuscript
silver stain according to the instruction manual (Invitrogen, Carlsbad, CA). In-gel digestion with trypsin was performed as described previously 28, 29 
Electrophoresis and immunoblotting
Electrophoresis and immunoblotting were carried out as described previously 21, 30, 31 .
Immunofluorescent staining
Immunofluorescent staining was carried out as described previously 22, 23 .
Preparation of adult cardiomyocytes
Ventricular cardiomyocytes were isolated from adult rat heart as described previously 32 . In brief, hearts were perfused with perfusion buffer [MEM, pH 7.3 containing taurin (5 mM), 2,3-butanedion monoxime (10 mM), creatine (50 mg/100 ml), and insulin (2 unit/100 ml)].
Enzymatic digestion was initiated by the addition of collagenase type B (0.5 mg/ml), collagenase type D (0.5 mg/ml), and protease type XIV (0.02 mg/ml) to the perfusion buffer.
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After 3 min of digestion, 50 µM CaCl 2 was added, and the solution was incubated for 7 min.
The ventricle was removed, cut into several pieces, and digested in a shaker (60-70 rpm) for 10 min at 37 °C. The supernatant containing the cardiomyocytes was placed in a sterilized tube, and gently centrifuged at 500 rpm for 1 min. The pellet was re-suspended in perfusion buffer at a volume equal to that of the incubation buffer [MEM containing bovine serum albumin (500 mg/100 ml) and CaCl 2 (150 mM)] to stop the enzymatic reaction.
Digital imaging of intracellular Ca
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Measurement of action potentials in adult cardiomyocytes
Action potentials were recorded in isolated ventricular cells from Wistar rats (body weight 200-300 g) by the perforated-patch clamp technique 33 . Pipettes had resistances in the range 
Working heart analysis
Hearts were excised from female ICR mice (8.5-12 wk of age; weight ~30g) after heparinization (15 U i.v.) under anesthesia with 2,2,2-tribromoethanol (5 mg i.p.). After all pulmonary veins in a heart with lung preparation were tied with silk threads, the lung was trimmed away and 18-gauge cannulae were tied onto the aortic stump and left auricle. The heart was mounted on an isolated heart perfusion apparatus ( DTXPlus (Nihon Koden, Japan) using a 26-gauge catheter inserted into the LV chamber from the apex. 34 .
Measurement of the activation of signal transduction molecules by flow cytometry
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The activation of signal transduction molecules was measured by cytometric bead array using flow cytometry. Briefly, H9c2 cells were incubated in DMEM without FBS for 24 hr, and were stimulated with M-LDH for 15 min. After the stimulation, a denaturing buffer was added to stop the reaction, and the phosphorylations of ERK1/2 (T202/Y2004), c-Jnu N-terminal kinase (JNK1/2) (T183/Y185), p38mitogen-actiated protein kinse (MAPK) (T180/Y182), and phospholipase Cγ (Y783) were measured according to the instruction manual (BD Bioscience, San Diego, CA). Standard curves based on recombinant proteins were prepared before the measurement.
Determination of isozymes of LDH activity in subjects.
LDH isozyme assay was determined using LDH isozymes Test Wako (Wako Pure Chemical Tokyo, Japan) according to the instruction manual. 
Results
Purification of survival factors released during sI/R
To purify survival factors released from cardiomyocytes, the supernatant of cultured cells exposed to sI/R was loaded onto a heparin Sepharose column. The proteins bound to the affinity column were eluted with a linear salt gradient, with the survival activity of the eluate being monitored by cell number after serum removal from culture medium (Fig. 1A) . Strong survival activities to inhibit cell death caused by the removal of serum were detected in two peaks (A and B), and the fractions showing stronger survival activity (peak A) were subjected to further purification by anion exchange column chromatography (Fig. 1B) . The bound proteins were eluted with a step-wise salt gradient, and strong survival activities were detected in two peaks (A1 and A2). The survival activity profile of peak A1 was almost the same as the absorbance profile at 280 nm (Fig. 1B) , and active fractions of peak A1 (fraction numbers 14 and 15) contained a single protein with a molecular mass of approximately 36 kDa (p36) on SDS-PAGE (Fig. 1C) . Peak A2 is currently under investigation.
Survival factor released during sI/R is M-LDH
The p36 protein was treated with trypsin under the conditions described in "Materials and
Methods", and subjected to peptide mass fingerprinting by MALDI-TOF-MS. when added to cell line H9c2 derived from embryonic heart (Fig. 1E) . Taken together, we conclude that the p36 protein is M-LDH.
M-LDH is released during sI/R
To confirm the release of M-LDH from cultured cells during sI/R, we carried out immunoblotting with an anti-M-LDH antibody using the supernatant of cells exposed to sI/R.
The amount of M-LDH protein in the supernatant increased after 24 hr of simulated reperfusion following simulated ischemia for 2 hr (Fig. 1F) ; exposure to medium without serum for a long time damages the cells so that no significant difference could not be detected between 48 hr serum (-) and sI/R. In contrast, the releases of G3PDH and PFK, other glycolytic enzymes in the cytosol, during sI/R, were reduced compared with the control cells, indicating that M-LDH is released relatively specifically during sI/R ( Fig. 1G and 1H ).
M-LDH has survival activity through protecting cardiomyocytes from oxidative stress-induced damage
Since oxidative stress induced by ischemia and reperfusion plays an important role in heart injury, we examined the effects of of the cardiomyocytes to a round shape ( Fig. 2A, C, and D) , and preserved cardiomyocyte contractility in response to electric stimulation (data not shown), indicating that M-LDH protects cardiomyocytes from oxidative stress-induced damage.
M-LDH inhibits [Ca 2+ ] i overload induced by an oxidative stress
To explore the mechanism involved in the survival activity of M-LDH, we examined the ] i increase ( Supplementary Fig. S1 ). We also examined the effects of significantly (Fig. 4F-H ). H 2 O 2 also prolonged the action potential duration; however, M-LDH had no effect on the prolongation of action potential duration by H 2 O 2 ( Fig. 4D and   I ).
M-LDH suppresses oxidative stress-or ischemia/reperfusion-induced decrease in contractility of isolated working heart
The effects of M-LDH on intact heart were examined using isolated working heart preparations ( Fig. 5 ). H 2 O 2 reduced the cardiac output from working heart preparation significantly and M-LDH suppressed the reduction of cardiac output caused by H 2 O 2 ; there were no significant differences in the cardiac output between hearts treated with H 2 O 2 in the presence of M-LDH and controls (Fig. 5A) . A brief ischemia-reperfusion reduced the cardiac output and systolic function (dP/dt max ) significantly and M-LDH suppressed the reduction of cardiac output and systolic function caused by this brief ischemia-reperfusion; there were no significant differences in the cardiac output and systolic function between hearts exposed to ischemia/reperfusion with M-LDH and controls ( Fig. 5B and C ). M-LDH had no effects on the function of the heart exposed to no ischemia (data not shown). The release of M-LDH was increased in the perfusion medium of intact heart exposed to ischemia and reperfusion as compared with that of control (Fig. 5D ). These observations indicated that M-LDH was involved in the recovery of heart function from ischemia.
M-LDH alters the phosphorylation levels of signal transduction molecules
To examine whether the survival activity of M-LDH involves any intracellular signaling pathways, the phosphorylation levels of signal transduction molecules ERK1/2, JNK1/2, p38MAPK, PLCγ were determined by cytometric bead array (CBA) using flow cytometry ( Fig. 6A-D) . CBA is an assay that carries out particle-based immunoassay using flow cytometry, and beads with different positions can be combined to create a multiplex assay. 
Incubation of H9c2 cells with M-LDH increased
M-LDH is released into blood of human patients exposed to ischemia-reperfusion.
We examined the release of M-LDH in patients exposed to ischemia by pump-oxygenator during open heart surgery. Total LDH activity in serum was significantly increased in patients subjected to the surgery with pump-oxygenator at 30 min after reperfusion and continued to increase for 72 hr (data not shown). Next, two LDH isozymes, the activities of M-LDH and LDH heart-type subunit (H-LDH) were determined in the serum of patients, because H-LDH was also known to be released from the heart in response to various injuries. H-LDH was
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rapidly released into the blood at 0.5 hr after reperfusion, and the release of H-LDH continued to increase at least for 72 hr after reperfusion ( Supplementary Fig. S2 ). In contrast, much less amounts of M-LDH was rapidly released into blood at 0.5 hr after reperfusion and the release was decreased within 48 hr after reperfusion ( Supplementary Fig. S2 ), suggesting that M-LDH rather than H-LDH may play an important role in the recovery from ischemia of the human heart.
Discussion
As shown in this study, many polypeptides are released into the supernatant of cells exposed to sI/R, a cell model of ischemia. Among these polypeptides, at least three have survival activities for cells exposed to stress by serum removal. Strong survival activities were found in an eluate containing a nearly pure single protein at the second step of purification by anion exchange column chromatography, suggesting that the major protein in . ] i overload due to the spontaneous Ca 2+ release from SR. Consistent with these data, pretreatment with M-LDH significantly improves the cardiac pump function of isolated mouse heart exposed to H 2 O 2 or ischemia-reperfusion, indicating that M-LDH has survival activity that protects the heart from oxidative stress and ischemic injury. ] i through the metabolic product lactate 45 . However, it is unlikely that lactate, a metabolic product of M-LDH, was acting as a survival factor in the present study, because the addition of lactate had no effect on the Ca 2+ overload induced by oxidative stress (data not shown). H-LDH, a heart subunit of M-LDH, also catalyzes the production of lactate, and large amounts of H-LDH are released from cardiomyocytes exposed to ischemia and reperfusion; however, no cell survival activity was detected in the fractions containing H-LDH. In addition, the coenzyme NADH was not required for the survival activity of M-LDH under our experimental conditions, indicating that M-LDH does not exert its survival activity as an enzyme lactate dehydrogenase.
In this study, the mechanism of M-LDH release during simulated ischemia and reperfusion remains to be clarified, but we could speculate that a mechanism other than release by a damaged membrane is involved because if M-LDH were released from the damaged membrane, G3PDH and PFK, also present in the cytosol, should also be detected
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during sI/R. However, the amounts of G3PDH and PFK released into the extracellular spaces decreased during sI/R. In addition, the rate of cell death among cells exposed to sI/R was 10 % or below under our experimental conditions, and was almost equal to that of control cells, suggesting that cell injury was not so severe (data not shown). LDH activity is often determined as a biomarker of cell damage. However, we found that more than 90 % of the activity released into the blood in a human ischemia heart model is due to the H-LDH isoform ( Supplementary Fig. S2 ), suggesting that LDH activity measured in cell death assay might not be necessarily corresponding to the M-LDH activity.
In conclusion, the present study provides strong evidence for a novel role of M-LDH in the recovery of heart function following ischemia. Two lines of evidence indicate that M-LDH acts through an intracellular signal transduction system: (1) 
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